Bono Mack backs tamper-proof painkiller legislation

Rep. Mary Bono Mack, R-Ca., has introduced legislation that would require pharmaceutical companies to make new opiate-based pills tamper-resistant. Bono Mack, who is co-chairman of the Congressional Caucus on Prescription Drug Abuse, says the “Stop the Tampering of Prescription Pills” (STOPP) Act would mandate that the FDA inform companies that refuse to manufacture tamper-proof versions to reformulate or withdraw their drug from the market.

But already-existing tamper-proof versions of drugs like OxyContin haven’t necessarily curbed the abuse epidemic. Many painkiller addicts have found ways to get their fix from such versions, or have switched to heroin.

Among Bono Mack’s other pending proposals are the Stop Oxy Abuse Act, which would restrict the use of any pain-relief drug containing oxycodone to “the relief of severe-only instead of moderate-to-severe pain,” and the Ryan Creedon Act of 2011 would require anyone who prescribes controlled substances to be educated on the risks such drugs pose to patients before they can register with the U.S. Drug Enforcement Administration. DEA registration is already required by federal law. Unlike President Barack Obama’s recent plan to curb prescription drug abuse – which allows pharmaceutical companies themselves to “educate” doctors on the risks of their products – the bill specifies that this training should be provided by a medical society, a state medical licensing board, an accredited continuing education provider, or “another organization that the Secretary [of Health and Human Services] determines is appropriate for providing such training or certification.”

The Creedon bill was named in honor of Ryan Creedon of Palm Desert, Calif., who suffered from a chronic addiction to OxyContin that ultimately resulted in his Feb. 2009 death. Read more about Ryan’s story here.

About Erin Marie Daly

I’m a freelance journalist based in San Francisco. My book on prescription drug and heroin addiction was published in August 2014 by Counterpoint Press.
This entry was posted in Informational, Pharmaceutical Industry, Policy & Regulation and tagged , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *